Literature DB >> 20237897

Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma >or=1 mm.

Friederike Egberts1, A Momkvist, J H Egberts, K C Kaehler, M Weichenthal, A Hauschild.   

Abstract

The histopathologic status of the sentinel node (SN) and the ulceration of the primary tumor are important indicators of the clinical outcome of melanoma patients. The purpose of this study was to investigate potential correlations between prognostic factors and the sentinel lymph node status as well as their influence on disease-free survival (DFS), distant metastases-free survival (DMFS), and overall survival (OS). The medical records of 259 melanoma patients who underwent sentinel lymph node dissection between 2000 and 2006 were analyzed. DFS, DMFS, and OS were assessed. A uni- and a multivariate analysis to determine prognostic factors were performed. Histologic type, Clark's level, and Breslow's tumor thickness were the only parameters that showed a significant correlation with a positive SN. The univariate analysis revealed SN positivity (DFS and DMFS: p < 0.001; OS: p = 0.039) and ulceration (DFS: p < 0.001; DMFS: p = 0.001; OS: p = 0.003) to be significant prognostic markers. However, ulceration was the only independent prognostic factor for OS that was upheld by the multivariate analysis (p = 0.006; HR 3.89; CI 1.48-10.27). In stage I/II melanoma patients, ulceration of the primary tumor was the strongest prognostic factor for RFS, DMFS, and OS and superior to the pathology status of the SN.

Entities:  

Mesh:

Year:  2009        PMID: 20237897     DOI: 10.1007/s13277-009-0002-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  U.K. guidelines for the management of cutaneous melanoma.

Authors:  D L L Roberts; A V Anstey; R J Barlow; N H Cox; J A Newton Bishop; P G Corrie; J Evans; M E Gore; P N Hall; N Kirkham
Journal:  Br J Dermatol       Date:  2002-01       Impact factor: 9.302

Review 2.  [Sentinel node biopsy. What are the facts?].

Authors:  M Möhrle; H Breuninger
Journal:  Hautarzt       Date:  2005-05       Impact factor: 0.751

3.  Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial.

Authors:  Joseph Meirion Thomas
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

4.  Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma.

Authors:  Donald L Morton; Alistair J Cochran; John F Thompson
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

5.  High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.

Authors:  A C J van Akkooi; J H W de Wilt; C Verhoef; W J Graveland; A N van Geel; M Kliffen; A M M Eggermont
Journal:  Eur J Cancer       Date:  2006-01-05       Impact factor: 9.162

6.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

Review 7.  Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma.

Authors:  Ronald E Perrott; L Frank Glass; Douglas S Reintgen; Neil A Fenske
Journal:  J Am Acad Dermatol       Date:  2003-10       Impact factor: 11.527

Review 8.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

Authors:  Thomas K Eigentler; Ulrich M Caroli; Peter Radny; Claus Garbe
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

9.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

10.  Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.

Authors:  F Roka; H Kittler; P Cauzig; C Hoeller; G Hinterhuber; K Wolff; H Pehamberger; E Diem
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.